What Wall Street Really Thinks of Medical Devices
The buzz on medical devices has been growing, with investors looking favorably at the lower start-up costs and shorter development and approval times compared with biomedical and pharmaceuticals. But what does Wall Street really think?
Rob Faulkner, who tracks medical devices as managing director at Thomas Weisel Partners, will provide an expert view of the industry at the upcoming meeting of SEMDA (Southeastern Medical Device Association). He will be followed by an expert panel who will offer a Southeastern perspective on the topic.